scholarly journals Moderate Consumption of Freeze-dried Blueberry Powder Increased Net Bone Calcium Retention in Healthy Postmenopausal Women: A Randomized Crossover Trial

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 32-32
Author(s):  
Joanna Hodges ◽  
Sisi Cao ◽  
Pamela Lachcik ◽  
Munro Peacock ◽  
George McCabe ◽  
...  

Abstract Objectives Preclinical studies suggest that blueberry consumption is associated with improved bone health. This study quantified changes in urinary excretion of the long-lived calcium radioisotope 41Ca to assess the dose-response effect of blueberries on bone loss in postmenopausal women. We hypothesized that blueberry consumption would reduce bone loss in a dose-dependent manner. Methods Healthy women at least 4 years past menopause were dosed with 50 nCi of 41Ca and completed a 5-mo equilibration period for 41Ca deposition in bone followed by a 6-wk control period. Subsequently, participants were assigned to a random sequence of 3 intervention periods, each corresponding to a low (17.5 g/d), medium (35 g/d), or high (70 g/d) dose of freeze-dried blueberry powder equivalent to 0.75, 1.5, or 3 cups of fresh blueberries. The blueberry powder was incorporated into granola bars, spread, and drinks consumed daily for 6 wk, followed by a 6-wk washout period. Urinary 41Ca: Ca ratio was measured by accelerator mass spectrometry in 24-h urine collected weekly during intervention and every 3 wk during washout. Serum 25-hydroxyvitamin D and calcium concentrations were assessed prior to each intervention. Serum bone resorption biomarkers and urinary polyphenols were measured at the end of each control and intervention period. Data were analyzed using a linear mixed model and repeated measures ANOVA. Results Fourteen healthy, non-osteoporotic (mean bone mineral density t-score: −1.33) women completed the study. Net bone calcium retention increased by 6% in the low (P < 0.01) and 4% in the medium (P < 0.05) dose intervention compared with the control and washout periods. The high dose had no significant effect on net bone calcium retention (P = 0.19). Urinary excretion of hippuric acid increased dose-dependently with blueberry consumption. No significant relationships were found between bone resorption biomarkers, 25-hydroxyvitamin D, or calcium and any of the interventions. Conclusions A hormetic response was observed to blueberry intake, whereby daily consumption of foods containing 17.5–35 g, but not 70 g, of freeze-dried blueberry powder increased net bone calcium retention. Moderate consumption of blueberries may be an effective strategy to attenuate bone loss in healthy postmenopausal women. Funding Sources NIH/NCCIH, Project Development Team within the ICTSI NIH/NCRR.

2016 ◽  
Vol 104 (3) ◽  
pp. 837-843 ◽  
Author(s):  
Steven A Jakeman ◽  
Courtney N Henry ◽  
Berdine R Martin ◽  
George P McCabe ◽  
Linda D McCabe ◽  
...  

2015 ◽  
Vol 145 (10) ◽  
pp. 2333-2340 ◽  
Author(s):  
Andreas Schild ◽  
Isabelle Herter-Aeberli ◽  
Karin Fattinger ◽  
Sarah Anderegg ◽  
Tim Schulze-König ◽  
...  

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 554-554 ◽  
Author(s):  
P. Lonning ◽  
J. Geisler ◽  
L. E. Krag ◽  
E. Løkkevik ◽  
T. Risberg ◽  
...  

554 Background: To evaluate potential detrimental effects of the aromatase inactivator exemestane on bone, 147 postmenopausal women with early breast cancer were randomised to receive either exemestane for 2 years or placebo (J. Clin. Oncol. 23 [22], 5126–5137, 2005). Exemestane increased the annual bone loss from the femoral neck (2.72%) compared to placebo (1.48%; P = 0.024) with a non-significant increase in the lumbar spine (exemestane 2.17% versus placebo 1.84%). The annual bone loss was higher than expected in the placebo arm. Methods: Various biomarkers involved in bone metabolism (25-hydroxyvitamin D, parathormone, calcium, estrogens, androgens) were analysed to elucidate their influence on bone status at baseline and BMD loss during treatment with exemestane compared to placebo. Results: Using a cut-off value of 30 ng/ml for 25-hydroxyvitamin D (J. Clin. Endocrinol. Metab. 90 [6], 3800–3801, 2005), the majority of study participants suffered from vitamin D deficiency (56 of 62 patients in the placebo group and 52 of 59 in the exemestane group). The mean levels (95% confidence interval) of vitamin D were 22.6 ng/ml (21.2 - 24.1) in the placebo group and 21.6 ng/ml (20.0 - 23.3) in the treatment group, revealing no differences between these groups. Low serum calcium levels at baseline were found to be significantly correlated to low BMD in the femoral neck in the exemestane group. However, individual levels of vitamin D, parathormone and estradiol at baseline were not correlated significantly to BMD. Conclusions: Considering an annual bone loss of 0.5% to be representative for postmenopausal women (Osteoporos. Int. 15, 881–886, 2004), our data indicate that vitamin D deficiency could be the most important factor elevating bone loss among patients treated with exemestane as well as in the placebo group. These findings, together with the observation of a moderate additional effect of exemestane on bone loss, underlines the need for proper vitamin D substitution of postmenopausal women in general and in breast cancer patients during treatment with aromatase inhibitors in particular. [Table: see text]


Biomedicines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 199
Author(s):  
Urara Tanaka ◽  
Shunichi Kajioka ◽  
Livia S. Finoti ◽  
Daniela B. Palioto ◽  
Denis F. Kinane ◽  
...  

DNA methylation controls several inflammatory genes affecting bone homeostasis. Hitherto, inhibition of DNA methylation in vivo in the context of periodontitis and osteoclastogenesis has not been attempted. Ligature-induced periodontitis in C57BL/6J mice was induced by placing ligature for five days with Decitabine (5-aza-2′-deoxycytidine) (1 mg/kg/day) or vehicle treatment. We evaluated bone resorption, osteoclast differentiation by tartrate-resistant acid phosphatase (TRAP) and mRNA expression of anti-inflammatory molecules using cluster differentiation 14 positive (CD14+) monocytes from human peripheral blood. Our data showed that decitabine inhibited bone loss and osteoclast differentiation experimental periodontitis, and suppressed osteoclast CD14+ human monocytes; and conversely, that it increased bone mineralization in osteoblastic cell line MC3T3-E1 in a concentration-dependent manner. In addition to increasing IL10 (interleukin-10), TGFB (transforming growth factor beta-1) in CD14+ monocytes, decitabine upregulated KLF2 (Krüppel-like factor-2) expression. Overexpression of KLF2 protein enhanced the transcription of IL10 and TGFB. On the contrary, site-directed mutagenesis of KLF2 binding site in IL10 and TFGB abrogated luciferase activity in HEK293T cells. Decitabine reduces bone loss in a mouse model of periodontitis by inhibiting osteoclastogenesis through the upregulation of anti-inflammatory cytokines via KLF2 dependent mechanisms. DNA methyltransferase inhibitors merit further investigation as a possible novel therapy for periodontitis.


2013 ◽  
Vol 8 (1-2) ◽  
Author(s):  
Kaori Kitamura ◽  
Kazutoshi Nakamura ◽  
Toshiko Saito ◽  
Ryosaku Kobayashi ◽  
Rieko Oshiki ◽  
...  

2009 ◽  
Vol 16 (6) ◽  
pp. 1093-1101 ◽  
Author(s):  
Jeanne W. Stewart ◽  
D. Lee Alekel ◽  
Laura M. Ritland ◽  
Marta Van Loan ◽  
Erik Gertz ◽  
...  

2013 ◽  
Vol 84 (9) ◽  
pp. 1243-1256 ◽  
Author(s):  
Amy E. Millen ◽  
Kathleen M. Hovey ◽  
Michael J. LaMonte ◽  
Mya Swanson ◽  
Christopher A. Andrews ◽  
...  

2011 ◽  
Vol 96 (6) ◽  
pp. 1677-1686 ◽  
Author(s):  
Helen M. Macdonald ◽  
Alexandra Mavroeidi ◽  
Lorna A. Aucott ◽  
Brian L. Diffey ◽  
William D. Fraser ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document